AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
Rhea-AI Summary
AIM ImmunoTech (NYSE American:AIM) will present in the Webull Corporate Connect Webinar Series, held virtually June 24–25, 2026.
The live webcast is scheduled for Wednesday, June 24, 2026, from 2:40–3:00 PM ET, presented by CEO Thomas Equels. Registration is available online.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AIM
On the day this news was published, AIM declined 2.55%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $270K from the company's valuation, bringing the market cap to $10.32M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
AIM was down about 5%, while peers showed mixed action: TNFA and PMCB declined sharply, BCLI and NCNA were up, and HCWB was flat. This mix suggests stock‑specific factors rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 18 | Clinical milestone | Positive | -7.5% | Final subject received first dose in Phase 2 DURIPANC pancreatic cancer study. |
| Jun 15 | Listing compliance | Positive | -4.0% | Regained NYSE American compliance after resolving stockholders’ equity deficiency. |
| Jun 09 | Dilutive financing | Negative | -20.5% | Registered direct and private placement financing for about $2.65M in gross proceeds. |
| Jun 08 | Interim trial update | Positive | +13.1% | Positive interim progress from Phase 2 DURIPANC trial of Ampligen plus Imfinzi. |
| Jun 04 | Investor video | Neutral | -19.2% | Virtual investor video on Ampligen’s potential in Ebola preparedness and related data. |
Recent AIM news often sees selling pressure even on positive milestones, with only one of five events showing a strong positive price response.
Regulatory & Risk Context
Short interest is elevated, indicating meaningful bearish positioning and the potential for higher volatility around news and financing or regulatory milestones.
An effective S-3/A shelf allows AIM to issue up to $100 million of various securities over time, providing financing flexibility but also ongoing dilution risk for existing shareholders.
Market Pulse Summary
This announcement focuses on AIM’s investor visibility, with the CEO presenting in a Webull webinar. Against recent financings, dilution overhang and elevated short positioning, investors may watch how effectively management communicates its pancreatic cancer and regulatory progress.
AI-generated analysis. Not financial advice.
Live webcast on Wednesday, June 24th at 2:40 PM ET
OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026.
Details for the presentation are as follows:
Date and Time: Wednesday, June 24, 2026 at 2:40 – 3:00 PM ET
Presenter: Thomas Equels, AIM ImmunoTech’s Chief Executive Officer
Registration Link: HERE
About Webull Financial
Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 16 markets across North America, Asia Pacific, Europe, Africa, and Latin America. Webull serves more than 27 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at www.webullcorp.com.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company does not undertake to update any forward-looking statements except as required by law.
For a discussion of risk factors, please see the Company’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, available at www.sec.gov.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com